Vaginal Laser Therapy: Promise vs Evidence
SaveVaginal laser therapy lacks strong evidence for menopause dryness and painful sex: in sham-controlled trials, fractional CO2 laser generally did not beat the placebo procedure. Major menopause society guidance advises against energy-based devices outside research, citing reported burns and scarring, while proven options like vaginal estrogen cost far less.
Last updated: July 2026History
What is vaginal laser therapy?
Vaginal laser therapy uses a fractional CO2 or Er:YAG device to deliver controlled heat to the vaginal wall, aiming to stimulate collagen and thicken tissue. Marketed under names such as MonaLisa Touch, it is promoted for dryness, painful sex, and mild urinary symptoms of the genitourinary syndrome of menopause, which affects up to 1 in 2 postmenopausal women 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. Clinics typically sell it as a series of 3 in-office sessions over about 12 weeks, with periodic touch-ups, often costing hundreds to thousands of dollars out of pocket. The theory is that heat-driven remodeling restores moisture and elasticity. Whether that biological idea translates into real symptom relief is exactly where the evidence becomes shaky. The marketing has moved faster than the proof.
Does vaginal laser actually work?
The most rigorous studies to date do not show that vaginal laser beats a placebo. In sham-controlled trials, where some women received a real laser and others an identical-feeling fake procedure, symptom improvement was similar in both groups 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. Because dryness and discomfort often improve with attention, expectation, and time, uncontrolled before-and-after reports can look impressive while proving little. Menopause society guidance concludes that current evidence is insufficient to recommend laser for genitourinary symptoms 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. Higher-quality, longer trials are still needed to know whether any subgroup truly benefits, and randomized comparisons remain the fairest test of a treatment's real effect. For now, the honest summary is that proof of benefit over placebo is lacking, not that benefit is definitively impossible.
Is vaginal laser safe?
Safety, not just effectiveness, is part of the concern with vaginal laser. Regulators have warned that marketing these devices for dryness, painful sex, or vaginal rejuvenation is not supported, and reported adverse effects include burns, scarring, and lasting pain 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. Because the treatment applies heat to delicate tissue, harm is possible even when benefit is unproven. Major menopause society guidance therefore recommends against routine use outside a research study 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. This caution carries more weight given that safer, better-studied treatments already exist for the same symptoms. Weighing a costly, unproven procedure that carries real risks against proven alternatives is the core of the decision, and the balance currently favors the established options.
What are the proven alternatives?
Proven treatments for genitourinary symptoms already exist and cost far less than laser. Low-dose vaginal estrogen relieves dryness and painful sex more effectively than placebo, often within about 12 weeks, in Cochrane-reviewed trials, and non-hormonal moisturizers and lubricants help milder cases 2Ref 2Lethaby A, Ayeleke RO, Roberts H (2016).Local oestrogen for vaginal atrophy in postmenopausal women.This Cochrane review found low-dose vaginal estrogen relieves vaginal atrophy symptoms, including dryness and painful sex, more effectively than placebo.. Prasterone inserts and the oral pill ospemifene are additional evidence-based options for moderate-to-severe symptoms 3Ref 3American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG Practice Bulletin 213 reviews evidence-based treatments for genitourinary syndrome of menopause and painful sex, including vaginal estrogen, prasterone, and ospemifene.. These changes often begin in the perimenopausal transition, deepen after menopause around ages 45 to 55, and can also appear during breastfeeding, so the right option depends on life stage and preference 4Ref 4World Health Organization (2024).Menopause (fact sheet).The WHO menopause fact sheet states menopause typically occurs between ages 45 and 55, with symptoms often beginning in the perimenopausal transition.. Where symptoms are mild, simple moisturizers may be enough; where they are severe, hormonal options work well. Laser sits outside this list because its benefit remains unproven.
When to ask a clinician about vaginal laser
A clinician can help you weigh vaginal laser against treatments with stronger evidence for your symptoms. Worsening pain, unusual bleeding, or new burning after any vaginal procedure is a reason to seek clinician review rather than to wait it out 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. A gynecologist or menopause-focused clinician can explain what the sham-controlled trials actually found and match you with proven options like vaginal estrogen, prasterone, or moisturizers 3Ref 3American College of Obstetricians and Gynecologists (2019).Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213.ACOG Practice Bulletin 213 reviews evidence-based treatments for genitourinary syndrome of menopause and painful sex, including vaginal estrogen, prasterone, and ospemifene.. Because roughly 50% of postmenopausal women have genitourinary symptoms and effective, lower-cost care exists, spending on an unproven device is rarely the first step 1Ref 1The North American Menopause Society (Menopause Society) (2020).The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.. Gale can help you prepare for that conversation and sort marketing claims from evidence.
Common questions
Related
Sexual health
Dilator Therapy: Retraining Muscles Step by StepSexual health
Prasterone (Vaginal DHEA): How It HelpsSexual health
Libido Supplements: What's Actually in Them
Say it back
How would you explain this to someone you love?
Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.
After a vaginal procedure, watch for
- —Worsening or severe pain after a vaginal laser procedure is a reason to seek clinician review
- —Unusual or heavy vaginal bleeding after a procedure is a reason to seek prompt clinician evaluation
- —New burning, scarring, or non-healing sores after treatment are a reason to arrange clinician review
- —Fever or spreading pain after a procedure is a reason to seek same-day clinician care
This article is general health education, not medical advice. Decisions about vaginal laser or proven alternatives should be made with a gynecologist or menopause-focused clinician who knows your health history.
Did this answer your question?
References
- 1.The North American Menopause Society (Menopause Society) (2020). The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. doi:10.1097/GME.0000000000001609 ✓The North American Menopause Society 2020 genitourinary syndrome of menopause position statement concludes evidence is insufficient to recommend energy-based (laser) therapy for genitourinary symptoms, notes reported adverse effects and a regulatory safety warning, and recommends against routine use outside research.
- 2.Lethaby A, Ayeleke RO, Roberts H (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD001500.pub3 ✓This Cochrane review found low-dose vaginal estrogen relieves vaginal atrophy symptoms, including dryness and painful sex, more effectively than placebo.
- 3.American College of Obstetricians and Gynecologists (2019). Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003324 ✓ACOG Practice Bulletin 213 reviews evidence-based treatments for genitourinary syndrome of menopause and painful sex, including vaginal estrogen, prasterone, and ospemifene.
- 4.World Health Organization (2024). Menopause (fact sheet). World Health Organization (WHO). link ✓The WHO menopause fact sheet states menopause typically occurs between ages 45 and 55, with symptoms often beginning in the perimenopausal transition.
4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy